ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ACP-017’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACP-017 overview
Small molecule is under development for the treatment of solid tumors including head and neck squamous-cell carcinoma (HNSCC), other HPV-associated cancers, melanoma, cutaneous squamous cell carcinoma (cSCC), colon cancer, merkel cell carcinoma, anal cancer, vulvar cancer, penile cancer, vaginal cancer, cervical cancer, esophageal cancer, triple-negative breast cancer, hepatocellular carcinoma, non-small cell lung cancer, oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer and oral cavity cancer. The drug candidate is a long acting prodrug of resiquimod administered through intratumoral route. It acts by targeting toll-like receptor (TLR) 7 and 8. It is developed based on the TransCon technology platform.
Ascendis Pharma overview
Ascendis Pharma is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist and TransCon IL-2 ß/?, an interleukin-2 variant that activates the IL-2 receptor beta/gamma (IL-2Rß/?) for the treatment of cancer. Ascendis Pharma utilizes its proprietary TransCon technology platform to develop its drugs. The company operates in the US, Germany and Denmark. Ascendis Pharma is headquartered in Hellerup, Denmark.
For a complete picture of ACP-017’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.